CA
INZY

CHI Advisors’s Inozyme Pharma INZY Stock Holding History

CHI Advisors’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$5.33M Buy
1,270,027
+75,000
+6% +$382K 2.11% 12
2023
Q2 		$6.66M Sell
1,195,027
-147,164
-11% -$870K 2.02% 11
2023
Q1 		$7.69M Sell
1,342,191
-862,685
-39% -$2.28M 2.04% 10
2022
Q4 		$2.32M Buy
2,204,876
+208,599
+10% +$365K 0.62% 16
2022
Q3 		$5.35M Sell
1,996,277
-37,525
-2% -$136K 1.44% 13
2022
Q2 		$9.7M Buy
2,033,802
+1,141,745
+128% +$4.97M 3.71% 8
2022
Q1 		$3.65M Hold
892,057
– – 1.55% 17
2021
Q4 		$6.08M Sell
892,057
-28,207
-3% -$244K 2.02% 13
2021
Q3 		$10.7M Sell
920,264
-7,000
-0.8% -$109K 3.11% 9
2021
Q2 		$15.8M Hold
927,264
– – 3.68% 8
2021
Q1 		$18.4M Sell
927,264
-68,132
-7% -$1.5M 3.68% 10
2020
Q4 		$20.5M Sell
995,396
-13,721
-1% -$327K 5.79% 7
2020
Q3 		$26.5M Buy
+1,009,117
New +$25.1M 9.44% 3

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CHI Advisors's INZY Position: Q3 2023 in Review

CHI Advisors increased its Inozyme Pharma (INZY) stake by 6.3% in Q3 2023, buying an estimated $382K and bringing the position to 1,270,027 shares worth $5.33M. The position accounts for 2.11% of the portfolio, ranked #12.

CHI Advisors first reported a position in INZY in Q3 2020 and has held it in 13 quarters since. The position peaked at $26.5M in Q3 2020. 77 funds tracked by Wall St. Rank hold INZY as of Q3 2023.

  • CHI Advisors held 1,270,027 shares of Inozyme Pharma worth $5.33M as of Q3 2023.
  • CHI Advisors bought 75,000 Inozyme Pharma shares in Q3 2023, an estimated $382K.
  • Inozyme Pharma made up 2.11% of CHI Advisors's portfolio in Q3 2023, its #12 holding.
  • CHI Advisors first reported a position in Inozyme Pharma in Q3 2020 and has held it in 13 quarters since.
  • CHI Advisors's Inozyme Pharma position peaked at $26.5M in Q3 2020.
  • 77 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.